A new weight loss pill called amycretin has shown impressive results in helping people lose significant amounts of weight in just three months.
According to a recent study presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain, participants who took the highest dose of amycretin lost up to 13% of their body weight during the 12-week trial.
The study was conducted by Novo Nordisk, a well-known pharmaceutical company based in Denmark. Amycretin is different from other weight loss medications because it combines the effects of two natural hormones in the body: amylin and glucagon-like peptide-1 (GLP-1).
These hormones play important roles in controlling appetite and managing hunger levels. Amylin helps slow down food intake and makes people feel full faster, while GLP-1 reduces hunger by signaling to the brain that the stomach is full.
There are already weight loss treatments on the market that target these hormones, but most of them require regular injections. Amycretin is unique because it is available as a daily pill, making it much easier and more comfortable to use. For many people, the idea of taking a pill instead of injections could be a major benefit, encouraging them to stick with the treatment.
The study was a Phase I clinical trial, which means it was an early stage of research mainly focused on testing the pill’s safety and initial effectiveness. It involved adults with a Body Mass Index (BMI) of 25.0 to 39.9, who were overweight or obese but did not have diabetes.
The participants were randomly divided into groups; some received amycretin in different doses, while others took a placebo, which is a pill that looks the same but has no active ingredients.
Over the course of 12 weeks, participants taking the highest dose of amycretin (2 x 50 mg) lost an average of 13.1% of their body weight. Those on a smaller dose (50 mg) lost about 10.4%. In comparison, the placebo group lost only about 1.1% of their body weight, showing that amycretin had a clear and significant impact.
One interesting aspect of the study was that participants taking amycretin continued to lose weight consistently throughout the 12 weeks and did not reach a point where their weight loss stopped.
This suggests that if they continued the treatment for a longer time, they might lose even more weight. This steady reduction in body weight is important because many other treatments tend to slow down or stop working after a few months.
The researchers also looked at the safety of amycretin during the trial. Most of the side effects were mild or moderate, mainly related to the digestive system. Some participants reported nausea and vomiting, but these issues were generally manageable and did not cause major problems.
The study concluded that amycretin appeared to be safe and well-tolerated for people without diabetes who are overweight or obese.
The study’s authors are optimistic that amycretin could become a convenient and effective option for weight loss. Since it targets two important appetite-regulating hormones in one pill, it may work better than some of the current treatments available.
However, they also emphasized that more research is needed to confirm these findings. Larger and longer-term studies will be important to understand the full effects and safety of the drug over time.
For now, amycretin’s early trial results are promising. It offers hope for people who struggle with weight loss, especially those who prefer a simple, once-daily pill over more invasive treatments like injections. If further studies confirm these initial results, amycretin could become a game-changer in the fight against obesity.
If you care about weight loss, please read studies that hop extract could reduce belly fat in overweight people, and early time-restricted eating could help lose weight.
For more health information, please see recent studies that Mediterranean diet can reduce belly fat much better, and Keto diet could help control body weight and blood sugar in diabetes.
Copyright © 2025 Knowridge Science Report. All rights reserved.
